November 16, 2020 Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
January 7, 2020 Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors
December 17, 2019 Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders
April 30, 2019 Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
April 16, 2019 Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery
